FENC

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) is a biopharmaceutical company founded in 1996 and headquartered in Research Triangle Park, North Carolina. Originally incorporated as Adherex Technologies Inc., the company changed its name to Fennec Pharmaceuticals in September 2014 to reflect its focused mission on pediatric oncology. The company went public in September 2017 and has since established itself as a specialized player in the rare disease pharmaceutical space, specifically targeting the prevention of chemotherapy-induced hearing loss in cancer patients.